


Product Name : Cerdulatinib
Cat. No. : PC-73204
CAS No. : 1198300-79-6
Molecular Formula : C₂₀H₂₇N₇O₃S
Molecular Weight : 445.54
Target : JAK
Solubility : 10 mM in DMSO



Biological Activity

Cerdulatinib (PRT062070) is a potent, ATP-competitive, orally active dual **SYK/JAK** inhibitor with IC₅₀ of 32 nM (**Syk**), 0.5-12 nM (JAK1/2/3, **Tyk2**).

Cerdulatinib (PRT062070) has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma; Cerdulatinib (PRT062070) demonstrates specificity towards JAK1/JAK3 and TYK2, but not JAK2-mediated responses at cellular level, does not inhibit TCR signaling or PKC signaling in whole blood.

Cerdulatinib (PRT062070) blocks cell cycle in both ABC and GCB subtypes of DLBCL via inhibition of RB phosphorylation and down-regulation of cyclin E.

Cerdulatinib (PRT062070) induces cell cycle arrest and apoptosis under the condition of BCR stimulation in DLBCL cell lines. Cerdulatinib (PRT062070) suppressed inflammation and autoantibody generation in a rat collagen-induced arthritis model and blocked B-cell activation and splenomegaly in a mouse model of chronic B-cell antigen receptor stimulation.

References

Coffey G, et al. *J Pharmacol Exp Ther*. 2014 Dec;351(3):538-48.

Ma J, et al. *Oncotarget*. 2015 Dec 22;6(41):43881-96.

Blunt MD, et al. *Clin Cancer Res*. 2017 May 1;23(9):2313-2324.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com